Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Merger or Acquisition (July 2024)
13 slides from Collegium Pharmaceutical's merger presentation, Jul 29, 2024
Slide 1: Collegium to Acquire Ironshore Therapeutics
Collegium to Acquire Ironshore Therapeutics July 29, 2024 | Nasdaq: COLL
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat
Slide 3: Strategic Rationale
Strategic Rationale Michael Heffernan, Chairman and Interim President & Chief Executive Officer
Slide 4: Highly Accretive Commercial-Stage Acquisition With Strong Growth Potential
Highly Accretive Commercial - Stage Acquisition With Strong Growth Potential Building a Leading, Diversified Specialty Pharmaceutical Company Maximize Pain Portfolio 4 • Conduct disciplined business development focused on commercial - stage, durable assets • Pay down debt • Opportunistically return
Slide 5: Ironshore Acquisition Aligns with All Strategic Objectives
Ironshore Acquisition Aligns with All Strategic Objectives x Differentiated, commercial - stage assets to diversify specialty pharmaceutical portfolio Addition of Jornay PM ® establishes a commercial presence in neurology (ADHD) with a highly differentiated product, diversifying portfolio x Signific
Slide 6: Commercial Opportunity
Commercial Opportunity Scott Dreyer, Executive Vice President & Chief Commercial Officer
Slide 7: Expanding Commercial Presence into Neurology
7 Expanding Commercial Presence into Neurology • Highly differentiated central nervous system (CNS) stimulant prescription medicine for the treatment of attention deficit hyperactivity disorder (ADHD) in people six years of age and older in the U.S. • Only stimulant ADHD medication with convenient e
Slide 8: Jornay PM Poised for Rapid Growth in the ADHD Market
8 Jornay PM Poised for Rapid Growth in the ADHD Market +5% CAGR in total ADHD prescriptions from 2019 - 2023 LARGE AND EXPANDING ADHD MARKET STRONG PRESCRIBER BASE & MARKET ACCESS SIGNIFICANT GROWTH IN JORNAY PRESCRIPTIONS 310K 490K 2022 2023 +58% +32% Year - over - year growth in H1’24 COMMERCIAL O
Slide 9: Financial Overview & Transaction Details
Financial Overview & Transaction Details Colleen Tupper, Executive Vice President & Chief Financial Officer
Slide 10: Transaction Details
Transaction Details Consideration • Collegium to acquire all outstanding shares of Ironshore for $525M in cash • Potential $25M in additional consideration if Jornay PM net revenue exceeds a defined threshold in 2025 Financing • Funded by existing Collegium cash on hand and $646M 5 - year term loan
Slide 11: Closing Remarks
Closing Remarks Michael Heffernan, Chairman and Interim President & Chief Executive Officer
Slide 12: Creating Long-Term Value Through Operational Execution
12 Creating Long - Term Value Through Operational Execution 12 DELIVER ON Financial commitments of top - and bottom - line growth: • Integrate and maximize the full potential of Jornay PM • Achieve record revenue, adjusted EBITDA and net income • Generate record free cash flow STRATEGICALLY Deploy c
Slide 13: Q&A
Q&A
Collegium Pharmaceutical — Merger or Acquisition (July 2024) on 6ix